Prova EducationContextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL (CME)

Patient Selection for ADCs in First-Line DLBCL

Deepen your understanding of the dynamic landscape of bispecific antibodies and antibody-drug conjugates in lymphoma treatment, as this program navigates the recent advancements for Hodgkin, follicular, and diffuse large B-cell lymphoma with expert insight.

Key Points:

• The FDA approved Polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated DLBCL and HGBL patients with an IPI score of 2 or more on April 19, 2023.
• Participants should be equipped to assess the efficacy and safety outcomes from recent trials in classical Hodgkin lymphoma (cHL).
• The program aims to facilitate the integration of recent clinical trial data to optimize treatment selection and survival outcomes for patients with cHL.
• The course intends to familiarize physicians with the rationale for newly approved therapies for the treatment of follicular lymphoma (FL) and those under evaluation.
• Participants will be able to apply the safety and efficacy of bispecific antibodies or antibody-drug conjugates being evaluated in patients with DLBCL.

Additional Points:

• Participants are expected to apply recent clinical trial data of bispecific antibodies into treatment planning for patients with FL.
• The course guides the selection process of patients with DLBCL who are eligible for newer therapies.
• The activity targets the educational needs of medical oncologists, hematology oncologists, and pathologists.

Conclusion:

• The CME program provides in-depth insight into the ever-evolving landscape of bispecific antibodies and antibody-drug conjugates in lymphoma treatment, thereby enhancing the skills and knowledge of professionals in the field.

Hematology/Oncology Latest Posts

• 18 Foods to Avoid to Reduce Cancer RiskOctober 21, 2024
• Is Luspatercept the New Standard of Care in Transfusion-Dependent Low-Risk Myelodysplastic Syndromes?October 21, 2024
• Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s LymphomaOctober 21, 2024
• Hematologic Cancer after Gene Therapy for Cerebral AdrenoleukodystrophyOctober 17, 2024

Accredidation and Credit Designation Statements
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.